CN103018317A - Novel non-standard-dependence quantitative analysis method based on study on homologous/similar compound structure-mass-spectrum response relationship - Google Patents
Novel non-standard-dependence quantitative analysis method based on study on homologous/similar compound structure-mass-spectrum response relationship Download PDFInfo
- Publication number
- CN103018317A CN103018317A CN2013100000045A CN201310000004A CN103018317A CN 103018317 A CN103018317 A CN 103018317A CN 2013100000045 A CN2013100000045 A CN 2013100000045A CN 201310000004 A CN201310000004 A CN 201310000004A CN 103018317 A CN103018317 A CN 103018317A
- Authority
- CN
- China
- Prior art keywords
- compounds
- mass
- homologous
- series
- quantitative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical group 0.000 title claims abstract description 112
- 238000004445 quantitative analysis Methods 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 title claims abstract description 18
- 238000001819 mass spectrum Methods 0.000 title claims abstract description 13
- 238000004949 mass spectrometry Methods 0.000 claims abstract description 27
- 239000000126 substance Substances 0.000 claims abstract description 19
- 238000011160 research Methods 0.000 claims abstract description 16
- 239000011159 matrix material Substances 0.000 claims abstract description 14
- 238000004458 analytical method Methods 0.000 claims abstract description 13
- 238000005516 engineering process Methods 0.000 claims abstract description 9
- 238000004451 qualitative analysis Methods 0.000 claims abstract description 4
- 238000002347 injection Methods 0.000 claims description 17
- 239000007924 injection Substances 0.000 claims description 17
- 239000009064 mailuoning Substances 0.000 claims description 11
- -1 alkaloid compounds Chemical class 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 7
- 238000013467 fragmentation Methods 0.000 claims description 5
- 238000006062 fragmentation reaction Methods 0.000 claims description 5
- 230000037361 pathway Effects 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000001228 spectrum Methods 0.000 claims description 4
- 238000004617 QSAR study Methods 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 241000411851 herbal medicine Species 0.000 claims description 2
- 240000000031 Achyranthes bidentata Species 0.000 claims 1
- 241000205585 Aquilegia canadensis Species 0.000 claims 1
- 241001523681 Dendrobium Species 0.000 claims 1
- 241000013557 Plantaginaceae Species 0.000 claims 1
- 229930013930 alkaloid Natural products 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 238000004364 calculation method Methods 0.000 claims 1
- 238000012512 characterization method Methods 0.000 claims 1
- 230000007613 environmental effect Effects 0.000 claims 1
- 229930182494 ginsenoside Chemical class 0.000 claims 1
- 229940089161 ginsenoside Drugs 0.000 claims 1
- 239000002917 insecticide Chemical class 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000000419 plant extract Substances 0.000 claims 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical class 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 238000012795 verification Methods 0.000 abstract description 2
- 238000005457 optimization Methods 0.000 abstract 1
- 150000002500 ions Chemical class 0.000 description 10
- 238000011002 quantification Methods 0.000 description 10
- 150000007524 organic acids Chemical class 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- UIAFKZKHHVMJGS-UHFFFAOYSA-N 2,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1O UIAFKZKHHVMJGS-UHFFFAOYSA-N 0.000 description 2
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- LBKFGYZQBSGRHY-UHFFFAOYSA-N 3-hydroxy-4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1O LBKFGYZQBSGRHY-UHFFFAOYSA-N 0.000 description 2
- IJFXRHURBJZNAO-UHFFFAOYSA-N 3-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC(O)=C1 IJFXRHURBJZNAO-UHFFFAOYSA-N 0.000 description 2
- WHSXTWFYRGOBGO-UHFFFAOYSA-N 3-methylsalicylic acid Chemical compound CC1=CC=CC(C(O)=O)=C1O WHSXTWFYRGOBGO-UHFFFAOYSA-N 0.000 description 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- LPNBBFKOUUSUDB-UHFFFAOYSA-N p-toluic acid Chemical compound CC1=CC=C(C(O)=O)C=C1 LPNBBFKOUUSUDB-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- JMSVCTWVEWCHDZ-UHFFFAOYSA-N syringic acid Chemical compound COC1=CC(C(O)=O)=CC(OC)=C1O JMSVCTWVEWCHDZ-UHFFFAOYSA-N 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- AFDXODALSZRGIH-QPJJXVBHSA-N (E)-3-(4-methoxyphenyl)prop-2-enoic acid Chemical compound COC1=CC=C(\C=C\C(O)=O)C=C1 AFDXODALSZRGIH-QPJJXVBHSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- VEEPGIBHWRABJA-UHFFFAOYSA-N 1-benzyl-3,5-dimethylpyrazol-4-amine Chemical compound CC1=C(N)C(C)=NN1CC1=CC=CC=C1 VEEPGIBHWRABJA-UHFFFAOYSA-N 0.000 description 1
- FEGVSPGUHMGGBO-UHFFFAOYSA-N 2-methoxy cinnamic acid Natural products COC1=CC=CC=C1C=CC(O)=O FEGVSPGUHMGGBO-UHFFFAOYSA-N 0.000 description 1
- YTFVRYKNXDADBI-SNAWJCMRSA-N 3,4,5-trimethoxycinnamic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1OC YTFVRYKNXDADBI-SNAWJCMRSA-N 0.000 description 1
- DAUAQNGYDSHRET-UHFFFAOYSA-N 3,4-dimethoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1OC DAUAQNGYDSHRET-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- RURHILYUWQEGOS-VOTSOKGWSA-N 4-Methylcinnamic acid Chemical compound CC1=CC=C(\C=C\C(O)=O)C=C1 RURHILYUWQEGOS-VOTSOKGWSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-GMZLATJGSA-N 5-Caffeoyl quinic acid Natural products O[C@H]1C[C@](O)(C[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-GMZLATJGSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- YTFVRYKNXDADBI-UHFFFAOYSA-N O-Methylsinapic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1OC YTFVRYKNXDADBI-UHFFFAOYSA-N 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- ONJSZLXSECQROL-UHFFFAOYSA-N alpha-hydroxyhippuric acid Natural products OC(=O)CNC(=O)C1=CC=CC=C1O ONJSZLXSECQROL-UHFFFAOYSA-N 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- ZGRRONMCJIREIE-UHFFFAOYSA-N benzyl n-[1-(4-chlorophenyl)-3-pyrrolidin-1-ylpropyl]-n-methylcarbamate Chemical compound C=1C=CC=CC=1COC(=O)N(C)C(C=1C=CC(Cl)=CC=1)CCN1CCCC1 ZGRRONMCJIREIE-UHFFFAOYSA-N 0.000 description 1
- 229940114055 beta-resorcylic acid Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- AFDXODALSZRGIH-UHFFFAOYSA-N p-coumaric acid methyl ether Natural products COC1=CC=C(C=CC(O)=O)C=C1 AFDXODALSZRGIH-UHFFFAOYSA-N 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000013441 quality evaluation Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- YIBXWXOYFGZLRU-UHFFFAOYSA-N syringic aldehyde Natural products CC12CCC(C3(CCC(=O)C(C)(C)C3CC=3)C)C=3C1(C)CCC2C1COC(C)(C)C(O)C(O)C1 YIBXWXOYFGZLRU-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
Description
技术领域 technical field
本技术发明属于分析领域,涉及同系/类似化合物的定量分析,特别是复杂基质样品中不存在标准品的化合物的定量分析方法。The technical invention belongs to the field of analysis, and relates to the quantitative analysis of homologous/similar compounds, especially the quantitative analysis method of compounds that do not have standard substances in complex matrix samples.
背景技术 Background technique
在草药、环境、食品和制药等复杂基质研究领域中,多组分同步定量能够揭示其中关键物质或潜在活性化合物的含量,对于整体质量控制和效应/毒性评估非常重要。然而,与定性分析相比,定量分析却要面临更多的问题和挑战。例如现已有许多非靶标分析策略,可不依赖标准品对未知化合物进行结构推测,但对于定量分析而言,由于各化合物的响应各异,标准品的缺乏已成为一个非常大的桎梏;此外,对于定量分析而言,系统的方法学考证也比定性分析的要求更为严格,需要对线性范围、准确度、精密度、稳定性、提取回收率、介质效应等一系列项目进行考察。In complex matrix research fields such as herbal medicine, environment, food and pharmaceuticals, multi-component simultaneous quantification can reveal the content of key substances or potential active compounds, which is very important for overall quality control and effect/toxicity assessment. However, compared with qualitative analysis, quantitative analysis faces more problems and challenges. For example, there are many non-target analysis strategies that can predict the structure of unknown compounds without relying on standards, but for quantitative analysis, the lack of standards has become a very big shackle because of the different responses of each compound; in addition, For quantitative analysis, systematic methodological research is also more stringent than qualitative analysis, and a series of items such as linear range, accuracy, precision, stability, extraction recovery rate, and medium effect need to be investigated.
在复杂体系中,同系/类似化合物往往是有机化合物的主要存在形式,这些化合物可能以整体或协同的形式发挥生物效应。以往的研究中,常以一个或一些现有标准品的且在体系中含量较高的化合物作为评价指标来代表同系化合物进行定量分析、质量评价或进行进一步的药物代谢动力学研究,但该思路存在着明显的局限性,由于一些化合物或代谢产物仍可能在低浓度条件下产生生物效应或毒性反应,因而不能被简单地忽略。In complex systems, homologous/similar compounds are often the main form of organic compounds, and these compounds may exert biological effects in a holistic or synergistic form. In previous studies, one or some existing standard compounds with high content in the system were often used as evaluation indicators to represent homologous compounds for quantitative analysis, quality evaluation or further pharmacokinetic research, but this idea There are obvious limitations, since some compounds or metabolites may still produce biological effects or toxic reactions at low concentrations, and thus cannot be simply ignored.
近年来,分析仪器特别是高分辨质谱的发展为复杂体系中化合物的分析提供了便利,与此同时,一些半定量或相对定量的方法学也相继被提出,来克服复杂体系定量中标准品难以获得的瓶颈。例如有人提出以同系/系列化合物中一个化合物的标准曲线作为参照,对其余化合物直接或通过分子量校正进行定量;有人先采用一系列化合物,研究其在特定仪器中响应的相对关系,既而在以后的定量中可仅用一个化合物,即可实现这些化合物的绝对定量;也有人提出了“提取物标准曲线”的概念,评价同系/系列化合物在体内的药代动力学过程。但这些方法终究局限于相对含量的估算,不能够准确外推不存在标准品的化合物的实际浓度,未能真正摆脱标准品的限制。In recent years, the development of analytical instruments, especially high-resolution mass spectrometry, has facilitated the analysis of compounds in complex systems. At the same time, some semi-quantitative or relative quantitative methodologies have also been proposed to overcome the difficulty of standard products in the quantification of complex systems. get the bottleneck. For example, someone proposes to use the standard curve of a compound in the same series/series of compounds as a reference to quantify the remaining compounds directly or through molecular weight calibration; someone first uses a series of compounds to study the relative relationship of their responses in a specific instrument, and then later In quantification, only one compound can be used to achieve absolute quantification of these compounds; the concept of "extract standard curve" has also been proposed to evaluate the pharmacokinetic process of homologous/serial compounds in vivo. However, these methods are limited to the estimation of relative content after all, and cannot accurately extrapolate the actual concentration of compounds without standard substances, and cannot really get rid of the limitation of standard substances.
除了分析领域的进展之外,一些计算机辅助的化学信息学策略也已经应用于制药和环境领域的研究,诸如药物先导物的发现,复杂体系中系列化合物构效关系研究等。在这些计算机辅助手段中,应用得较多的主要为分子对接/药效团分析和定量构效关系/结构保留时间关系研究。然而,这些技术在复杂体系系列化合物定量研究中暂无应用实例,其原因可能为化合物定量的影响因素较多,且尚未找到合适的量化指标,用于表征化合物的仪器响应等。In addition to the progress in the field of analysis, some computer-aided cheminformatics strategies have also been applied to research in the fields of pharmaceuticals and the environment, such as the discovery of drug leads, the study of the structure-activity relationship of a series of compounds in complex systems, etc. Among these computer-aided methods, the most widely used ones are molecular docking/pharmacophore analysis and quantitative structure-activity relationship/structure retention time relationship research. However, these techniques have no application examples in the quantitative research of complex system series of compounds. The reason may be that there are many factors affecting the quantification of compounds, and no suitable quantitative indicators have been found to characterize the instrument response of compounds.
本技术发明旨在解决同系/系列化合物定量过程中标准品缺乏的问题。通过选取合适的能表征化合物质谱响应的量化指标,建立化合物内在理化结构性质和质谱响应之间的关系。通过模型的建立和验证,可解释在用质谱对同系/系列化合物定量时对其响应有影响的关键理化参数,预测同系/系列化合物在质谱中的响应,以实现不依赖于标准品的复杂基质中同系/系列化合物的定量。The technical invention aims to solve the problem of lack of standard products in the quantitative process of homologous/serial compounds. By selecting an appropriate quantitative index that can characterize the mass spectrometry response of the compound, the relationship between the intrinsic physical and chemical structure properties of the compound and the mass spectrometry response is established. Through the establishment and verification of the model, it can explain the key physical and chemical parameters that affect the response of homologous/serial compounds when mass spectrometry is used to quantify them, and predict the response of homologous/serial compounds in mass spectrometry, so as to realize complex matrices that do not depend on standards Quantification of homologous/serial compounds in
发明内容 Contents of the invention
本技术发明的目的是提供一种新的基于同系/类似化合物结构-质谱响应关系研究的不依赖标准品的定量分析方法,通过如下步骤完成:The purpose of this technical invention is to provide a new quantitative analysis method based on the study of homologous/similar compound structure-mass spectrum response relationship that does not depend on standard substances, and is completed by the following steps:
1、选取一系列同系/类似化合物进行其质谱定量方法学研究及考证:1. Select a series of homologous/similar compounds for mass spectrometric quantitative methodological research and research:
选取尽可能多且简单易得的标准品建立质谱定量方法,确定其定量范围,并对准确度、精密度、稳定性、介质效应、提取回收率等项目进行系统的方法学考证。Select as many and easy-to-obtain standards as possible to establish a mass spectrometry quantitative method, determine its quantitative range, and conduct systematic methodological research on accuracy, precision, stability, medium effect, extraction recovery and other items.
2、根据在一定浓度范围内建立的各化合物的标准曲线,进行截距为零的线性拟合:2. According to the standard curve of each compound established within a certain concentration range, perform linear fitting with zero intercept:
考虑到化合物的标准曲线包含斜率和截距两项,斜率体现化合物的响应强弱,而截距的存在主要为校正低浓度样品的准确度,在理想情况下化合物的标准曲线应过零点,故进行截距为零的线性拟合,以拟合斜率作为表征化合物响应的指标。Considering that the standard curve of the compound contains two items of slope and intercept, the slope reflects the response strength of the compound, and the existence of the intercept is mainly to correct the accuracy of low-concentration samples. Ideally, the standard curve of the compound should cross the zero point, so A linear fit with zero intercept was performed, and the slope of the fit was used as an index to characterize the compound response.
3、用分子模拟软件对化合物进行结构优化,计算与其各理化性质相关的分子描述符:3. Use molecular simulation software to optimize the structure of the compound, and calculate the molecular descriptors related to its physical and chemical properties:
用分子模拟软件对标准品化合物的结构进行处理,计算其优化构象,并计算在优化构象条件下化合物的理化参数描述符,如分子量、极性、能量、电性等。Use molecular simulation software to process the structure of the standard compound, calculate its optimal conformation, and calculate the physical and chemical parameter descriptors of the compound under the optimal conformation conditions, such as molecular weight, polarity, energy, electrical properties, etc.
4、用分子模拟软件进行化合物结构(包括各理化参数描述符、分析条件中与质谱响应相关的参数)与质谱响应(线性拟合标准曲线的斜率)之间关系的建立及验证:4. Use molecular simulation software to establish and verify the relationship between the compound structure (including various physical and chemical parameter descriptors, parameters related to the mass spectrometry response in the analysis conditions) and the mass spectrometry response (the slope of the linear fitting standard curve):
对于已有的化合物,挑选部分作为训练集,建立化合物结构与质谱响应之间的关系,表现形式可为多元一次回归方程(MLR)、人工神经网络(BNN)等,并用其余的化合物作为预测集,对该方程进行验证。需保证所建立的方程具有较好的拟合度和解释度,所包含的自变量具有一定的实际意义,且需防止方程的过拟合。For the existing compounds, select a part as the training set, establish the relationship between the compound structure and the mass spectrometry response, which can be expressed in the form of multiple linear regression equation (MLR), artificial neural network (BNN), etc., and use the rest of the compounds as the prediction set , to verify the equation. It is necessary to ensure that the established equation has a good degree of fitting and interpretation, the included independent variables have certain practical significance, and the overfitting of the equation must be prevented.
5、应用相关质谱技术对复杂基质样品进行定性分析,从总离子流图谱中寻找及确定主要的离子峰,并通过准确分子质量、碎裂途径等质谱信息对筛选的该系列化合物进行结构鉴定:5. Apply relevant mass spectrometry technology to qualitatively analyze complex matrix samples, find and determine the main ion peaks from the total ion current spectrum, and identify the structure of the series of compounds screened through mass spectrometry information such as accurate molecular mass and fragmentation pathway:
本技术发明中应用了加拿大ABI公司生产的TripleTOF 5600(LC/MS-Q-TOF)系统,对中药复方注射剂脉络宁注射液中的有机酸类化合物进行了搜寻及结构鉴定。首先根据该类化合物的特征碎片离子和碎裂途径进行筛选,再根据所筛选出化合物的分子式及碎片信息进行结构鉴定。In the invention of this technology, the TripleTOF 5600 (LC/MS-Q-TOF) system produced by the Canadian ABI company was used to search and identify the organic acid compounds in the traditional Chinese medicine compound injection Mailuoning injection. Firstly, screening is carried out according to the characteristic fragment ions and fragmentation pathways of such compounds, and then structural identification is carried out according to the molecular formula and fragment information of the screened compounds.
6、根据先前建立的结构-质谱响应关系方程,计算所鉴定出系列化合物的线性拟合标准曲线的斜率,即预测该系列化合物的标准曲线:6. According to the previously established structure-mass spectrum response relationship equation, calculate the slope of the linear fitting standard curve of the identified series of compounds, that is, predict the standard curve of the series of compounds:
对所鉴定出的化合物用分子模拟软件进行结构优化,计算分子描述符,并将其代入之前建立的结构-质谱响应关系方程中,计算出其拟合斜率值,得其拟合标准曲线。The molecular simulation software was used to optimize the structure of the identified compounds, and the molecular descriptors were calculated, which were substituted into the previously established structure-mass spectrum response relationship equation, and the fitting slope value was calculated to obtain the fitting standard curve.
7、用该系列化合物的拟合标准曲线,对这些化合物进行定量分析,求得其在复杂基质样品中的浓度,即实现不依赖于标准品的定量分析:7. Use the fitting standard curve of this series of compounds to perform quantitative analysis on these compounds, and obtain their concentrations in complex matrix samples, that is, to achieve quantitative analysis independent of standards:
将化合物与内标峰面积的比值代入拟合标曲,求得其估算浓度,若该估算浓度位于之前方法学建立的定量范围内,则该估算具有较高的准确度。Substitute the ratio of the peak area of the compound to the internal standard into the fitted standard curve to obtain its estimated concentration. If the estimated concentration is within the quantitative range established by the previous methodology, the estimation has high accuracy.
本技术发明具有以下优点:The technical invention has the following advantages:
1、对于系列同系/类似化合物,能得出对其质谱响应有影响的关键理化参数,可用于化合物质谱响应高低的预估;1. For a series of homologous/similar compounds, the key physical and chemical parameters that affect the mass spectrometry response can be obtained, which can be used to predict the level of the mass spectrometry response of the compound;
2、通过已建立的化合物结构与质谱响应之间关系的模型,可对实际不存在标准品的复杂体系中其它同系/类似化合物进行较为准确的定量;2. Through the established model of the relationship between compound structure and mass spectrometry response, other homologous/similar compounds in complex systems that do not actually exist in standard products can be more accurately quantified;
3、本发明切实可行,且具有普遍适用性的特点,不局限于复杂基质样品中某特定类别的同系/类似化合物的分析。3. The present invention is practicable and has universal applicability, and is not limited to the analysis of a certain type of homologous/similar compounds in complex matrix samples.
附图说明 Description of drawings
图1;有机酸标准品(a)、空白辅料制剂(b)、脉络宁注射液(c)在负离子模式下的总离子流色谱图。Figure 1: Total ion chromatograms of organic acid standard (a), blank excipient preparation (b), Mailuoning injection (c) in negative ion mode.
图2;所构建的化合物结构-质谱响应关系中,预测值和实际值之间的比较图。Figure 2; The comparison between the predicted value and the actual value in the constructed compound structure-mass spectrum response relationship.
具体实施方式 Detailed ways
实施例1;脉络宁注射液中有机酸类成分的定量分析
1、选取一系列同系/类似化合物进行其质谱定量方法学研究及考证;1. Select a series of homologous/similar compounds for mass spectrometric quantitative methodological research and research;
选取苯甲酸(A1)、4-甲基苯甲酸(A2)、水杨酸(A3)、3-羟基苯甲酸(A4)、4-羟基苯甲酸(A5)、肉桂酸(A6)、2-羟基-3-甲基苯甲酸(A7)、原儿茶酸(A8)、2,4-二羟基苯甲酸(A9)、4-甲基肉桂酸(A10)、香豆酸(A11)、香草酸(A12)、异香草酸(A13)、没食子酸(A14)、4-甲氧基肉桂酸(A15)、2-甲氧基肉桂酸(A16)、咖啡酸(A17)、3,4-二甲氧基苯甲酸(A18)、阿魏酸(A19)、丁香酸(A20)、3,4,5-三甲氧基肉桂酸(A21)、绿原酸(A22)、1,5-二氧咖啡酰奎尼酸(A23)、3,4-二氧咖啡酰奎尼酸(A24)、3,5-二氧咖啡酰奎尼酸(A25)这25个有机酸标准品进行定量方法学建立及考察,内标选取2-羟基马尿酸。运用加拿大ABI公司生产的TripleTOF 5600(LC/MS-Q-TOF)系统建立系列有机酸的质谱定量方法,并对线性范围、准确度、精密度、稳定性等项目进行方法学考证。有机酸标准品在特定分析条件下的总离子流色谱图见图1(a)。Select benzoic acid (A1), 4-methylbenzoic acid (A2), salicylic acid (A3), 3-hydroxybenzoic acid (A4), 4-hydroxybenzoic acid (A5), cinnamic acid (A6), 2- Hydroxy-3-methylbenzoic acid (A7), protocatechuic acid (A8), 2,4-dihydroxybenzoic acid (A9), 4-methylcinnamic acid (A10), coumaric acid (A11), vanilla acid (A12), isovanillic acid (A13), gallic acid (A14), 4-methoxycinnamic acid (A15), 2-methoxycinnamic acid (A16), caffeic acid (A17), 3,4-di Methoxybenzoic acid (A18), ferulic acid (A19), syringic acid (A20), 3,4,5-trimethoxycinnamic acid (A21), chlorogenic acid (A22), 1,5-dioxo Caffeoylquinic acid (A23), 3,4-dioxocaffeoylquinic acid (A24), and 3,5-dioxocaffeoylquinic acid (A25) were used for quantitative methodological establishment of 25 organic acid standards And investigation, internal standard selection 2-hydroxyhippuric acid. The TripleTOF 5600 (LC/MS-Q-TOF) system produced by Canada ABI Company was used to establish a mass spectrometry quantitative method for a series of organic acids, and the methodological research was carried out on linear range, accuracy, precision, stability and other items. The total ion chromatograms of organic acid standards under specific analysis conditions are shown in Figure 1(a).
2、根据在一定浓度范围内建立的各化合物的标准曲线,进行截距为零的线性拟合;2. According to the standard curve of each compound established within a certain concentration range, perform linear fitting with zero intercept;
在50ng/ml-10ug/ml浓度的定量范围内,进行截距为零的线性拟合,并考察其定量准确度。结果如表1所示。In the quantitative range of 50ng/ml-10ug/ml concentration, carry out linear fitting with zero intercept, and examine its quantitative accuracy. The results are shown in Table 1.
3、用分子模拟软件对化合物进行结构优化,计算与其各理化性质相关的分子描述符;3. Use molecular simulation software to optimize the structure of the compound, and calculate the molecular descriptors related to its physical and chemical properties;
用Sybyl-X 1.2(Tripos Inc.,St.Louis,USA)软件对标准品化合物的进行结构处理,计算其优化构象;运用Discovery Studio 2.5(Accelrys Inc.,San Diego,USA)软件计算在优化构象条件下化合物的理化参数描述符,如分子量、极性、能量、电性等。Use Sybyl-X 1.2 (Tripos Inc., St.Louis, USA) software to process the structure of the standard compound, and calculate its optimal conformation; use Discovery Studio 2.5 (Accelrys Inc., San Diego, USA) software to calculate the optimal conformation Physicochemical parameter descriptors of compounds under conditions, such as molecular weight, polarity, energy, electrical properties, etc.
4、用分子模拟软件进行化合物结构(包括各理化参数描述符、分析条件中与质谱响应相关的参数)与质谱响应(线性拟合标准曲线的斜率)之间关系的建立及验证;4. Use molecular simulation software to establish and verify the relationship between the compound structure (including various physical and chemical parameter descriptors, parameters related to the mass spectrometry response in the analysis conditions) and the mass spectrometry response (the slope of the linear fitting standard curve);
为了避免拟合斜率出现负值,选取化合物线性拟合标准曲线斜率的自然对数值(LN(SlopeRate))作为表征其质谱响应的量化参数。对于现有的25化合物,挑选其中的20个作为训练集,以多元一次回归方程(MLR)的形式建立了其结构与质谱响应之间的关系,并用其余的5个化合物作为预测集,对该MLR方程进行验证。拟合的结果见表2(a)、表2(b)和图2。In order to avoid the negative value of the fitting slope, the natural logarithmic value (LN(SlopeRate)) of the slope of the linear fitting standard curve of the compound was selected as a quantitative parameter to characterize its mass spectral response. For the existing 25 compounds, 20 of them were selected as the training set, and the relationship between the structure and the mass spectrometry response was established in the form of a multiple regression equation (MLR), and the remaining 5 compounds were used as the prediction set. The MLR equation is verified. The fitting results are shown in Table 2(a), Table 2(b) and Figure 2.
5、应用相关质谱技术对复杂基质样品进行定性分析,从总离子流图谱中寻找及确定主要的离子峰,并通过准确分子质量、碎裂途径等质谱信息对筛选的该系列化合物进行结构鉴定;5. Apply relevant mass spectrometry technology to qualitatively analyze complex matrix samples, find and determine the main ion peaks from the total ion current spectrum, and identify the structure of the series of compounds screened through mass spectrometry information such as accurate molecular mass and fragmentation pathway;
应用加拿大ABI公司生产的TripleTOF 5600(LC/MS-Q-TOF)系统,对中药复方注射剂脉络宁注射液中的有机酸类化合物进行了搜寻及结构鉴定,将用甲醇稀释100倍的注射液直接进样,方法同前。空白辅料制剂和脉络宁注射液的总离子流色谱图见图1(b)和1(c)。通过与空白辅料制剂的图谱对比挑选出注射液中的药源性化合物,根据该类化合物的特征碎片离子和碎裂途径进行筛选,挑选出其中的有机酸类化合物,再根据所筛选出化合物的分子式及碎片信息进行进一步的结构鉴定。共从脉络宁注射液中鉴定出34个有机酸类化合物,结果见表3。Using the TripleTOF 5600 (LC/MS-Q-TOF) system produced by the Canadian ABI company, the organic acid compounds in the traditional Chinese medicine compound injection Mailuoning injection were searched and identified. The injection diluted 100 times with methanol was directly Sample injection, the method is the same as before. The total ion current chromatograms of the blank excipient preparation and Mailuoning injection are shown in Figure 1(b) and 1(c). The drug-derived compounds in the injection were selected by comparison with the spectra of the blank excipient preparations, screened according to the characteristic fragment ions and fragmentation pathways of the compounds, and the organic acid compounds were selected, and then the compounds were selected according to the Molecular formula and fragment information for further structural identification. A total of 34 organic acid compounds were identified from Mailuoning injection, and the results are shown in Table 3.
6、根据先前建立的结构-质谱响应关系方程,计算所鉴定出系列化合物的线性拟合标准曲线的斜率,即预测该系列化合物的标准曲线;6. According to the previously established structure-mass spectrum response relationship equation, calculate the slope of the linear fitting standard curve of the identified series of compounds, that is, predict the standard curve of the series of compounds;
对脉络宁注射液中所鉴定出的有机酸类化合物用Sybyl-X 1.2软件进行结构优化,再用Discovery Studio 2.5软件计算分子描述符,并将其代入之前建立的结构-质谱响应关系方程中,计算出各化合物的拟合斜率值,得其拟合标准曲线。The structure of the organic acid compounds identified in Mailuoning injection was optimized with Sybyl-X 1.2 software, and the molecular descriptors were calculated with Discovery Studio 2.5 software, and substituted into the previously established structure-mass spectrum response relationship equation, Calculate the fitting slope value of each compound to obtain its fitting standard curve.
7、用该系列化合物的拟合标准曲线,对这些化合物进行定量分析,求得其在复杂基质样品中的浓度,即实现不依赖于标准品的定量分析;7. Use the fitting standard curve of this series of compounds to conduct quantitative analysis on these compounds, and obtain their concentration in complex matrix samples, that is, to achieve quantitative analysis independent of standards;
将各有机酸化合物峰面积与内标峰面积的比值代入拟合标曲,求得其估算浓度。对于有标准品的化合物,同时进行绝对定量,并将其绝对定量和用该法定量所得的结果进行比较,结果见表4。Substitute the ratio of the peak area of each organic acid compound to the peak area of the internal standard into the fitting standard curve to obtain its estimated concentration. For the compounds with standard substances, the absolute quantification was carried out at the same time, and the absolute quantification was compared with the results obtained by this method. The results are shown in Table 4.
从表4可以看出,从脉络宁注射液中所鉴定出的34个化合物,有16个化合物有标准品。通过比较这16个化合物的绝对定量和拟合定量结果发现,该拟合结果具有较高的预测准确度,可对浓度在50ng/ml-10ug/ml范围内的有机酸类化合物进行较为准确的定量。本发明切实可行,具有普遍适用性的特点,也可用于复杂基质样品中其它类别同系/类似化合物的定量分析。It can be seen from Table 4 that among the 34 compounds identified in Mailuoning Injection, 16 compounds have standards. By comparing the results of absolute quantification and fitting quantification of these 16 compounds, it is found that the fitting result has a high prediction accuracy, and can be more accurate for organic acid compounds with concentrations in the range of 50ng/ml-10ug/ml Quantitative. The invention is practicable, has the characteristics of universal applicability, and can also be used for quantitative analysis of other types of homologous/similar compounds in complex matrix samples.
表2(a)MLR方程的回归及统计学考察Table 2(a) Regression and statistical investigation of the MLR equation
表2(b)MLR方程中的参数及系数Table 2(b) Parameters and coefficients in the MLR equation
表3脉络宁注射液中所鉴定出化合物的定性信息Table 3 Qualitative information of the compounds identified in Mailuoning Injection
表4脉络宁注射液中所鉴定出化合物的定量结果及比较Quantitative results and comparison of compounds identified in Table 4 Mailuoning Injection
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2013100000045A CN103018317A (en) | 2013-01-04 | 2013-01-04 | Novel non-standard-dependence quantitative analysis method based on study on homologous/similar compound structure-mass-spectrum response relationship |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2013100000045A CN103018317A (en) | 2013-01-04 | 2013-01-04 | Novel non-standard-dependence quantitative analysis method based on study on homologous/similar compound structure-mass-spectrum response relationship |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103018317A true CN103018317A (en) | 2013-04-03 |
Family
ID=47967156
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2013100000045A Pending CN103018317A (en) | 2013-01-04 | 2013-01-04 | Novel non-standard-dependence quantitative analysis method based on study on homologous/similar compound structure-mass-spectrum response relationship |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103018317A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108663428A (en) * | 2018-05-29 | 2018-10-16 | 北京理工大学 | A method of based on mobility electrophoretic determination matter dimensions |
CN109425663A (en) * | 2017-08-24 | 2019-03-05 | 湖南中烟工业有限责任公司 | One kind is assumed to decompose based on sparsity mixes mass spectrographic method with parsing |
CN111089908A (en) * | 2018-10-24 | 2020-05-01 | 中国科学院大连化学物理研究所 | Internal standards, internal standards, methods and kits for retention time alignment/correction |
CN113049631A (en) * | 2021-03-24 | 2021-06-29 | 海南红塔卷烟有限责任公司 | Instillation micro-extraction method for quantitative analysis of thermogravimetric escaping substances |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101071130A (en) * | 2007-06-14 | 2007-11-14 | 中国广州分析测试中心 | Method for establishing quality standard fingerprint spectrum of Chinese material medica |
CN101196498A (en) * | 2006-12-06 | 2008-06-11 | 中国科学院计算技术研究所 | A Prediction Method of Mass Spectrometry Mass Measurement Error |
EP2017622A1 (en) * | 2007-07-19 | 2009-01-21 | DKFZ Deutsches Krebsforschungszentrum, Stiftung des Öffentlichen Rechts | Method for determining the concentration of a molecule |
WO2011123837A2 (en) * | 2010-04-01 | 2011-10-06 | University Of Georgia Research Foundation, Inc. | Method and system using computer simulation for the quantitative analysis of glycan biosynthesis |
WO2012146787A1 (en) * | 2011-04-28 | 2012-11-01 | Philip Morris Products S.A. | Computer-assisted structure identification |
-
2013
- 2013-01-04 CN CN2013100000045A patent/CN103018317A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101196498A (en) * | 2006-12-06 | 2008-06-11 | 中国科学院计算技术研究所 | A Prediction Method of Mass Spectrometry Mass Measurement Error |
CN101071130A (en) * | 2007-06-14 | 2007-11-14 | 中国广州分析测试中心 | Method for establishing quality standard fingerprint spectrum of Chinese material medica |
EP2017622A1 (en) * | 2007-07-19 | 2009-01-21 | DKFZ Deutsches Krebsforschungszentrum, Stiftung des Öffentlichen Rechts | Method for determining the concentration of a molecule |
WO2011123837A2 (en) * | 2010-04-01 | 2011-10-06 | University Of Georgia Research Foundation, Inc. | Method and system using computer simulation for the quantitative analysis of glycan biosynthesis |
WO2012146787A1 (en) * | 2011-04-28 | 2012-11-01 | Philip Morris Products S.A. | Computer-assisted structure identification |
Non-Patent Citations (1)
Title |
---|
贠栋等: "结构描述符正交化及典型相关分析在饱和醇、醚质谱分类中的应用", 《应用化学》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109425663A (en) * | 2017-08-24 | 2019-03-05 | 湖南中烟工业有限责任公司 | One kind is assumed to decompose based on sparsity mixes mass spectrographic method with parsing |
CN109425663B (en) * | 2017-08-24 | 2021-06-15 | 湖南中烟工业有限责任公司 | A Method for Decomposing and Analyzing Mixed Mass Spectra Based on Sparsity Assumption |
CN108663428A (en) * | 2018-05-29 | 2018-10-16 | 北京理工大学 | A method of based on mobility electrophoretic determination matter dimensions |
CN111089908A (en) * | 2018-10-24 | 2020-05-01 | 中国科学院大连化学物理研究所 | Internal standards, internal standards, methods and kits for retention time alignment/correction |
CN113049631A (en) * | 2021-03-24 | 2021-06-29 | 海南红塔卷烟有限责任公司 | Instillation micro-extraction method for quantitative analysis of thermogravimetric escaping substances |
CN113049631B (en) * | 2021-03-24 | 2022-10-04 | 海南红塔卷烟有限责任公司 | Instillation micro-extraction method for quantitative analysis of thermogravimetric escaping substances |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Liu et al. | New advances in analytical methods for mass spectrometry-based large-scale metabolomics study | |
Maurer | Hyphenated mass spectrometric techniques—indispensable tools in clinical and forensic toxicology and in doping control | |
Schrimpe-Rutledge et al. | Untargeted metabolomics strategies—challenges and emerging directions | |
Rivier | Criteria for the identification of compounds by liquid chromatography–mass spectrometry and liquid chromatography–multiple mass spectrometry in forensic toxicology and doping analysis | |
Theodoridis et al. | Liquid chromatography–mass spectrometry based global metabolite profiling: a review | |
Chan et al. | Global urinary metabolic profiling procedures using gas chromatography–mass spectrometry | |
Dunn et al. | Measuring the metabolome: current analytical technologies | |
Fisher et al. | Approaches for assessing performance of high-resolution mass spectrometry–based non-targeted analysis methods | |
Mattoli et al. | Mass spectrometry‐based metabolomic analysis as a tool for quality control of natural complex products | |
Wang et al. | A strategy to identify and quantify closely related adulterant herbal materials by mass spectrometry-based partial least squares regression | |
Wu et al. | Quantitative structure–ion intensity relationship strategy to the prediction of absolute levels without authentic standards | |
Kirkwood et al. | Simultaneous, untargeted metabolic profiling of polar and nonpolar metabolites by LC‐Q‐TOF mass spectrometry | |
Lind et al. | The use of mass spectrometry for analysing metabolite biomarkers in epidemiology: methodological and statistical considerations for application to large numbers of biological samples | |
Su et al. | Dansylation isotope labeling liquid chromatography mass spectrometry for parallel profiling of human urinary and fecal submetabolomes | |
Sisco et al. | Development and evaluation of a synthetic opioid targeted gas chromatography mass spectrometry (GC‐MS) method | |
Mason et al. | Miniaturized 1H-NMR method for analyzing limited-quantity samples applied to a mouse model of Leigh disease | |
Wilson et al. | A perspective on the standards describing mass spectrometry-based metabolic phenotyping (metabolomics/metabonomics) studies in publications | |
Steuer et al. | Untargeted metabolomics approaches to improve casework in clinical and forensic toxicology—“Where are we standing and where are we heading?” | |
CN103018317A (en) | Novel non-standard-dependence quantitative analysis method based on study on homologous/similar compound structure-mass-spectrum response relationship | |
Jones et al. | An introduction to metabolomics and its potential application in veterinary science | |
Oesterle et al. | Exposomic biomonitoring of polyphenols by non-targeted analysis and suspect screening | |
CN116879477A (en) | A qualitative annotation method adapted to high-resolution mass spectrometry data from different instruments | |
Ji et al. | Rapid detection of nine synthetic cathinones in blood and urine by direct analysis in real‐time‐tandem mass spectrometry | |
Urban et al. | Complexity and pitfalls of mass spectrometry-based targeted metabolomics in brain research | |
Bjerrum | Metabonomics: analytical techniques and associated chemometrics at a glance |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130403 |